IPCP
TLSI icon

Iron Park Capital Partners’s TriSalus Life Sciences TLSI Stock Holding History

Iron Park Capital Partners’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-550,000
Closed -$5.46M – 2
2022
Q3 		$5.46M Hold
550,000
– – 73.55% 1
2022
Q2 		$5.42M Buy
550,000
+62,433
+13% +$614K 5.79% 3
2022
Q1 		$4.78M Buy
487,567
+432,450
+785% +$4.27M 4.02% 7
2021
Q4 		$545K Buy
+55,117
New +$548K 0.44% 38

Other funds holding TLSI

MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
DFCM
Dark Forest Capital Management San Juan, Puerto Rico $1.13B AUM 18.74% 1-Year Est. Return
SIA
SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.36B AUM 20.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Iron Park Capital Partners's TLSI Position: Q4 2022 in Review

Iron Park Capital Partners sold out of TriSalus Life Sciences (TLSI) in Q4 2022, closing a stake of 550,000 shares — an estimated $5.46M sold.

Iron Park Capital Partners first reported a position in TLSI in Q4 2021 and held it in 4 quarters. The position peaked at $5.46M in Q3 2022. 9 funds tracked by Wall St. Rank hold TLSI as of Q4 2022.

  • Iron Park Capital Partners reported no remaining TriSalus Life Sciences position as of Q4 2022 after selling out during the quarter.
  • Iron Park Capital Partners sold 550,000 TriSalus Life Sciences shares in Q4 2022, an estimated $5.46M.
  • Iron Park Capital Partners first reported a position in TriSalus Life Sciences in Q4 2021 and held it in 4 quarters.
  • Iron Park Capital Partners's TriSalus Life Sciences position peaked at $5.46M in Q3 2022.
  • 9 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q4 2022.

Based on Iron Park Capital Partners's 13F filing for Q4 2022, filed 31 Jan 2023.